Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 2:59 AM
Ignite Modification Date:
2025-12-25 @ 2:59 AM
NCT ID:
NCT02925533
Brief Summary:
This research study is studying a combination of two experimental drugs as a possible treatment for Bladder Cancer that recurred after treatment with standard therapy, or Bladder Cancer that got worse while on treatment with standard therapy.
The following interventions will be involved in this study:
* B-701
* Pembrolizumab
Detailed Description:
This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved B-701 as a treatment for any disease.
The FDA has not approved Pembrolizumab for Bladder Cancer but it has been approved for other uses.
This is the first time that B-701 in combination with Pembrolizumab will be given to humans.
In this research study, Investigators are...
* Testing the effectiveness and safety of the combination of two experimental drugs (B-701 and Pembrolizumab);
* Learning about the good and/or bad effects the drugs have on participants and their cancer;
* Administering B-701 and Pembrolizumab, which are antibodies (proteins that bind to other molecules), because...
* B-701 binds to a protein receptor called FGFR3 (fibroblast growth factor receptor 3). FGFR3 has been found to be present (expressed) or changed (mutated) on the surface of in many types of cancer cells. Targeting FGFR3 may inhibit cancer growth.
* Pembrolizumab binds to a protein cell surface receptor called PD-1, which is found on certain types of lymphocytes and which are also involved in many types of cancer;
* Treating participants with Pembrolizumab, which is approved by the FDA for the treatment of Metastatic Melanoma, a Cancer of the skin;
* Collecting blood and tissue samples and other related medical information to learn more about the development of cancer and predictors of response;
* And hoping to learn how the combination of study drugs work in the treatment of cancer to help develop new treatments.
Study:
NCT02925533
Study Brief:
Protocol Section:
NCT02925533